New research in The FASEB Journal indicates that delivering a cellular metabolite via tiny particles called nanolipisomes may augment the beneficial effects of certain anti-leukemia drugs.
Many drug-resistant tumors have dysfunctional metabolism of ceramide, a metabolite that promotes cell death. Investigators who previously demonstrated that augmenting ceramide can counter tumors’ drug resistance mechanisms have now shown that adding ceramide nanoliposomes can improve the efficacy of a standard chemotherapy regimen of venetoclax plus cytarabine in models of acute myeloid leukemia. The researchers also uncovered several mechanisms behind these effects.
“Ceramide-based therapeutics had been a decades long passion for senior author Dr. Mark Kester, who sadly passed away this summer, and we will continue his legacy to assess the utility of the ceramide nanoliposome in the clinic. This publication is part of the basis for clinical trials testing the potential of the ceramide nanoliposome in acute myeloid leukemia, which are expected to begin in 2023,” said corresponding author Todd Fox, PhD, of the University of Virginia.
URL Upon Publication: https://onlinelibrary.wiley.com/doi/10.1096/fj.202200765R
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact:
Sara Henning-Stout, newsroom@wiley.com
About the Journal
The FASEB Journal publishes high quality and impactful multidisciplinary research covering biology and biomedical sciences at every level of organization: atomic, molecular, cell, tissue, organ, organismic, and population. The journal’s scope includes the spectrum of biological and biomedical sciences as well as interdisciplinary research cutting across multiple fields and extending in related areas.
About Wiley
Wiley is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at Wiley.com, like us on Facebook and follow us on Twitter and LinkedIn.